Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis

Article2022

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

Ghassan K. Abou‐Alfa, Stephen L. Chan, Masatoshi Kudo, George Lau, Robin Kate Kelley, Junji Furuse, Wattana Sukeepaisarnjaroen, Yoon‐Koo Kang, Tu Van Dao, Enrico N. De Toni, Lorenza Rimassa, В. В. Бредер, Alexander Vasilyev, Alexandra Heurgué, Vincent C. Tam, Kabir Mody, Satheesh Chiradoni Thungappa, Philip He, Alejandra Negro, Bruno Sangro

Article2023

Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).

George Lau, Ann‐Lii Cheng, Bruno Sangro, Masatoshi Kudo, Robin Kate Kelley, Won Young Tak, Antonio Gasbarrini, María Reig, Ho Yeong Lim, David Tougeron, Enrico N. De Toni, Vincent C. Tam, Kabir Mody, Jun Gong, Carrie L. McCoy, Charu Gupta, Mallory Makowsky, Alejandra Negro, Ghassan K. Abou‐Alfa

Article2024

Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

George Lau, Ghassan K. Abou‐Alfa, Ann‐Lii Cheng, Wattana Sukeepaisarnjaroen, Tu Van Dao, Yoon‐Koo Kang, C. Satheesh, Masatoshi Kudo, Bruno Sangro, Robin Kate Kelley, Junji Furuse, Joong‐Won Park, Patrapim Sunpaweravong, Angelica Fasolo, Thomas Yau, Tomokazu Kawaoka, Sérgio Jobim Azevedo, María Reig, Éric Assenat, Mark Yarchoan, Aiwu Ruth He, Mallory Makowsky,

Article2025

Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study

Alba Sparacino, Gabriele Di Maria, Marco Vaccaro, Giuseppe Cabibbo, Calogero Cammà, María Reig, Robin Kate Kelley, Amit G. Singal, Ahmed O. Kaseb, Masatoshi Kudo, Lorenza Rimassa, David J. Pinato, Ciro Celsa, Tiziana Pressiani, Naoshi Nishida, Shadi Chamseddine, Ashwini Arvind, Michael Li, Marta Fortuny, Najib Ben Khaled, Massimo Iavarone, Hidenori Toyoda,

Article2024

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley, George Lau, Masatoshi Kudo, Wattana Sukeepaisarnjaroen, M. Yarchoan, Enrico N. De Toni, J. Furuse, Yoon‐Koo Kang, Peter R. Galle, Lorenza Rimassa, Alexandra Heurgué, Vincent C. Tam, Tu Van Dao, S.C. Thungappa, В. В. Бредер, Y. Ostapenko, María Reig, M. Makowsky, Michael J. Paskow, Charu Gupta, ,

Abstract

Discussion(0)

Related publications